Changsanye-factor oral liquor and clinical use

Abstract

The invention belongs to pharmaceutical preparations containing protein materials. It is an oral preparation of intestinal trefoil factor, which is characterized in that it contains intestinal trefoil factor as a pharmacodynamic active component, and also contains intestinal trefoil factor activator and intestinal trefoil factor protective agent. It is clinically used for the treatment of gastrointestinal ischemia-hypoxic injury, such as peptic ulcer, radiation enteritis, chronic gastritis, enteritis and other diseases caused by various reasons, and can rapidly promote the proliferation of gastrointestinal epithelial cells, Stabilizes the gastrointestinal mucus layer, does not interfere with glucose metabolism and promote gluconeogenesis, and has no side effects of promoting the expression of bacterial drug resistance genes and promoting the growth of tumor cells.

Description

1. Technical Field [0001] The invention belongs to a pharmaceutical preparation containing protein materials, and particularly relates to a biomedical preparation containing a specific growth factor-intestinal trefoil factor (ITF for short, the same hereinafter). 2. Background technology [0002] The gastrointestinal digestive tract is the corridor through which food and water lead to the body. It is often subject to mechanical and chemical (especially strong acid and alkali substances) impacts, and is often attacked by other harmful or toxic substances. More opportunities for loss. Modern medical research shows that the gastrointestinal tract is very sensitive to ischemic and hypoxic injury, and the gastrointestinal tract is one of the body's most vulnerable organs under various pathological conditions. Therefore, how to reduce gastrointestinal damage and promote damage repair is extremely important. Although the gastrointestinal protective drugs used clinically such as sucralfa...

AI Technical Summary

Problems solved by technology

But most of them are non-specific. In addition to promoting intestinal mucosal proliferation and repair, they also affect other cell functions. For example, growth hormone can interfere with glucose metabolism and promote gluconeogenesis, which limits its application in diabetic patients and severe trauma patients. Another example is fibroblast growth factor, insulin-like growth factor, etc., which have the side effects of promoting the expression of bacterial drug resistance genes and promoting the growth of tumor cells.

In conclusion, the current biopharmaceutical preparations prepared from the above-mentioned prodrugs have many defects in the treatment of gastrointestinal diseases